(0.03%) 5 101.28 points
(0.20%) 38 317 points
(0.04%) 15 935 points
(-1.30%) $82.76
(6.24%) $2.04
(0.07%) $2 348.90
(-0.23%) $27.47
(3.79%) $957.05
(-0.20%) $0.933
(-0.29%) $10.99
(-0.53%) $0.796
(1.67%) $93.41
1.51% HKD 17.48
Live Chart Being Loaded With Signals
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China...
Stats | |
---|---|
Volumen de hoy | 6.48M |
Volumen promedio | 5.62M |
Capitalización de mercado | 103.65B |
EPS | HKD0 ( 2024-03-26 ) |
Last Dividend | HKD0.0707 ( 2023-09-15 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 31.21 |
ATR14 | HKD0.0180 (0.10%) |
Volumen Correlación
Hansoh Pharmaceutical Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hansoh Pharmaceutical Correlación - Moneda/Commodity
Hansoh Pharmaceutical Finanzas
Annual | 2023 |
Ingresos: | HKD10.10B |
Beneficio Bruto: | HKD9.07B (89.78 %) |
EPS: | HKD0.520 |
FY | 2023 |
Ingresos: | HKD10.10B |
Beneficio Bruto: | HKD9.07B (89.78 %) |
EPS: | HKD0.520 |
FY | 2022 |
Ingresos: | HKD9.38B |
Beneficio Bruto: | HKD8.51B (90.73 %) |
EPS: | HKD0.440 |
FY | 2021 |
Ingresos: | HKD9.94B |
Beneficio Bruto: | HKD9.07B (91.24 %) |
EPS: | HKD0.460 |
Financial Reports:
No articles found.
Hansoh Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0500 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0500 (N/A) |
HKD0.141 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0771 | 2021-06-07 |
Last Dividend | HKD0.0707 | 2023-09-15 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD0.576 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.76 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.64 | |
Div. Directional Score | 8.95 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8476.HK | Ex Dividend Knight | 2023-08-22 | Annually | 0 | 0.00% | |
2039.HK | Ex Dividend Junior | 2023-07-25 | Annually | 0 | 0.00% | |
1109.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
0175.HK | Ex Dividend Junior | 2023-06-05 | Annually | 0 | 0.00% | |
3788.HK | Ex Dividend Knight | 2023-10-05 | Annually | 0 | 0.00% | |
1681.HK | Ex Dividend Knight | 2023-06-08 | Semi-Annually | 0 | 0.00% | |
0716.HK | Ex Dividend Junior | 2023-09-11 | Annually | 0 | 0.00% | |
2233.HK | Ex Dividend Junior | 2023-05-30 | Annually | 0 | 0.00% | |
1257.HK | No Dividend Player | 2023-09-12 | Annually | 0 | 0.00% | |
0316.HK | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.324 | 1.500 | 3.51 | 5.27 | [0 - 0.5] |
returnOnAssetsTTM | 0.0992 | 1.200 | 6.69 | 8.03 | [0 - 0.3] |
returnOnEquityTTM | 0.131 | 1.500 | 9.65 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.02 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.27 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.130 | -1.500 | 7.84 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.174 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.160 | 2.00 | 9.92 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.166 | -1.500 | 9.34 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.898 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.265 | 1.000 | 6.70 | 6.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.267 | 1.000 | 9.63 | 9.63 | [0.2 - 2] |
assetTurnoverTTM | 0.306 | 0.800 | -1.295 | -1.036 | [0.5 - 2] |
Total Score | 11.25 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 33.03 | 1.000 | 6.76 | 0 | [1 - 100] |
returnOnEquityTTM | 0.131 | 2.50 | 9.78 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.160 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.166 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.174 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 4.64 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.113 | 1.000 | 9.66 | 0 | [0.1 - 0.5] |
Total Score | 6.64 |
Hansoh Pharmaceutical
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico